MedTrace Logo

Beta-3 Enhanced Autonomic Therapy for POTS

NCT07585513 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-05-13

No results posted yet for this study

Summary

The study will test the hypothesis that mirabegron is more effective than a placebo in alleviating postural orthostatic tachycardia (POTS) symptoms.

Conditions

  • Postural Orthostatic Tachycardia Syndrome (POTS)

Interventions

DRUG

Mirabegron

This is a randomized placebo controlled double blind trial comparing mirabegron with placebo in treating POTS

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • Cedars-Sinai Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2028-05-31
Completion
2028-05-31
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07585513 on ClinicalTrials.gov